Evidence map›Paper›PMID 42694382›Full record

ArticleFrontiers in pharmacology2026

Angiotensin receptor blocker ameliorates the development of tubulointerstitial injury and fibrosis associated with tubular proteinuria observed in subclinical diabetic kidney disease.

Mariana R Campos, Pedro Henrique S R Seabra, Laura B F Oliveira, Vitória L Lacerda, Tawanne M Souza, Mariana C Moraes, Letícia Cristine C Dos Santos, Paula P Campos, Celso Caruso-Neves, Diogo B Peruchetti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariana R CamposDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Pedro Henrique S R SeabraDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Laura B F OliveiraDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Vitória L LacerdaDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Tawanne M SouzaDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Mariana C MoraesDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Letícia Cristine C Dos SantosDepartment of General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Paula P CamposDepartment of General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Celso Caruso-NevesCarlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Diogo B PeruchettiDepartment of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Subclinical Diabetic Kidney Disease ( Methods: For that, we developed streptozotocin (STZ)-induced type 1 DM [with normal levels of glomerular flow rate] in male Wistar rats, which were daily treated with 30 mg/kg/day losartan, a well-known ARB, via gavage for 6 consecutive weeks starting after induction of diabetes. Four experimental groups were generated: 1) CONT, normoglycemic rat; 2) ARB, normoglycemic rat treated with losartan; 3) Results: Comparing with the CONT group, the Discussion: Altogether, our findings indicated that ARB promotes renoprotective effects by attenuating AT1R-associated tubular damage and proteinuria of tubular origin observed in subDKD.

Indexed as

angiotensin receptor blocker (ARB)hyperglycemiaprotein reabsorptionproteinuriaproximal tubulerenin-angiotensin systemsubclinical diabetic kidney disease

Identifiers

PMID42694382
PMCPMC13538440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.